Khadija A. Sahan, I. Aziz, Sana Nadhir Dawood, Shaymaa S. Abdul Razzaq
{"title":"miR-146和miR-196在伊拉克乳腺癌患者样本中作为潜在生物标志物的评估","authors":"Khadija A. Sahan, I. Aziz, Sana Nadhir Dawood, Shaymaa S. Abdul Razzaq","doi":"10.21931/rb/css/2023.08.02.8","DOIUrl":null,"url":null,"abstract":"Breast cancer is a heterogeneous disease defined by molecular types and subtypes. It constitutes the most commonly-diagnosed cancer and the leading cause\nof cancer death in women worldwide, according to the International Agency for\nResearch on Cancer (IARC) World Cancer Reports in 2020. The study aimed to\nevaluate the miR-146 and miR-196 expression level and their association with\nthe ca15-3 serum level of the participants diagnosed with breast cancer. There\nwere 105 samples, three groups of 35 fresh blood samples and FFPE Tissue samples, which were collected as malignant, benign and healthy control. CA15-3\nconcentration was elevated in a malignant group with a mean equal to (36.14\nUnits/ml) in comparison to (27.07 Units/ml) for the benign group and (14.34\nUnits/ml) for the healthy control group (p<0.01). The results revealed that the expression of miR-146 in Malignant breast tumor tissue was (2.378 ±0.76) times\nmore, while in benign breast tissue, with the fold of expression (1.197 ±0.38) in\ncomparison with apparently healthy tissue. At the same time, the expression of\nmiR-196 in Malignant breast tumor tissue was (8.11 ±2.15) times more, while in\nbenign breast tissue, with a fold of expression (2.584 ±0.84) compared with apparently healthy tissue with highly significant differences.\nKeyword: Breast Cancer, miR-146, miR-196, ca15-3, FFPE","PeriodicalId":201642,"journal":{"name":"Sumer 2","volume":"45 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of miR-146 and miR-196 as potential biomarkers in a sample of\\nIraqi breast cancer patients\",\"authors\":\"Khadija A. Sahan, I. Aziz, Sana Nadhir Dawood, Shaymaa S. Abdul Razzaq\",\"doi\":\"10.21931/rb/css/2023.08.02.8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Breast cancer is a heterogeneous disease defined by molecular types and subtypes. It constitutes the most commonly-diagnosed cancer and the leading cause\\nof cancer death in women worldwide, according to the International Agency for\\nResearch on Cancer (IARC) World Cancer Reports in 2020. The study aimed to\\nevaluate the miR-146 and miR-196 expression level and their association with\\nthe ca15-3 serum level of the participants diagnosed with breast cancer. There\\nwere 105 samples, three groups of 35 fresh blood samples and FFPE Tissue samples, which were collected as malignant, benign and healthy control. CA15-3\\nconcentration was elevated in a malignant group with a mean equal to (36.14\\nUnits/ml) in comparison to (27.07 Units/ml) for the benign group and (14.34\\nUnits/ml) for the healthy control group (p<0.01). The results revealed that the expression of miR-146 in Malignant breast tumor tissue was (2.378 ±0.76) times\\nmore, while in benign breast tissue, with the fold of expression (1.197 ±0.38) in\\ncomparison with apparently healthy tissue. At the same time, the expression of\\nmiR-196 in Malignant breast tumor tissue was (8.11 ±2.15) times more, while in\\nbenign breast tissue, with a fold of expression (2.584 ±0.84) compared with apparently healthy tissue with highly significant differences.\\nKeyword: Breast Cancer, miR-146, miR-196, ca15-3, FFPE\",\"PeriodicalId\":201642,\"journal\":{\"name\":\"Sumer 2\",\"volume\":\"45 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sumer 2\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21931/rb/css/2023.08.02.8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sumer 2","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21931/rb/css/2023.08.02.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of miR-146 and miR-196 as potential biomarkers in a sample of
Iraqi breast cancer patients
Breast cancer is a heterogeneous disease defined by molecular types and subtypes. It constitutes the most commonly-diagnosed cancer and the leading cause
of cancer death in women worldwide, according to the International Agency for
Research on Cancer (IARC) World Cancer Reports in 2020. The study aimed to
evaluate the miR-146 and miR-196 expression level and their association with
the ca15-3 serum level of the participants diagnosed with breast cancer. There
were 105 samples, three groups of 35 fresh blood samples and FFPE Tissue samples, which were collected as malignant, benign and healthy control. CA15-3
concentration was elevated in a malignant group with a mean equal to (36.14
Units/ml) in comparison to (27.07 Units/ml) for the benign group and (14.34
Units/ml) for the healthy control group (p<0.01). The results revealed that the expression of miR-146 in Malignant breast tumor tissue was (2.378 ±0.76) times
more, while in benign breast tissue, with the fold of expression (1.197 ±0.38) in
comparison with apparently healthy tissue. At the same time, the expression of
miR-196 in Malignant breast tumor tissue was (8.11 ±2.15) times more, while in
benign breast tissue, with a fold of expression (2.584 ±0.84) compared with apparently healthy tissue with highly significant differences.
Keyword: Breast Cancer, miR-146, miR-196, ca15-3, FFPE